profit from every £100 of sales.
£0£100
Allergy Therapeutics
£0.01+2.76% today
-81.8% in 1 year
1-year low £0.011-year high £0.12
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Allergy Therapeutics sold, what it kept, and what it did with the cash.
Sales went from £72.8 million in 2022 to £55.0 million in 2025, with -£40.1 million of profit last year.
SalesProfit
Allergy Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from £100 of sales | Sales growth a year | Price per £1 of profit |
|---|---|---|---|
| Allergy Therapeutics | No profit yet | ||
 Merck KGaA | 24.8× · Fair price | ||
 Takeda Pharmaceutical | 101.0× · Very expensive | ||
 Galderma Group | 88.6× · Very expensive | ||
 Teva Pharmaceutical Industries | 36.1× · Expensive |
AI analysis
An AI analyst reads Allergy Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of GBP | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 73 | 60 | 55 | 55 | |
| 50 | 33 | 30 | 29 | |
| -12 | -35 | -34 | -28 | |
| -8 | -35 | -31 | -28 | |
| -14 | -43 | -39 | -40 | |
| -0.02 | -0.08 | -0.01 | -0.01 | |
| 68.0% | 55.8% | 53.9% | 53.2% | |
| -16.8% | -58.6% | -61.6% | -51.2% | |
| -18.9% | -72.3% | -70.0% | -72.9% |
Balance sheet
| In millions of GBP | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 73 | 68 | 66 | 68 |
| Cash | 20 | 15 | 13 | 13 |
| Total debt | 11 | 36 | 31 | 60 |
| Total liabilities | 35 | 64 | 59 | 96 |
| 38 | 4 | 7 | -28 | |
| 684 | 670 | 3,743 | 4,766 | |
| -18.6% | -73.6% | -68.6% | -76.4% | |
| -36.5% | -1,048.2% | -525.0% | 142.3% |
Cash flow
| In millions of GBP | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -14 | -29 | -32 | -28 | |
| 3 | 5 | 3 | 3 | |
| -17 | -34 | -36 | -32 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 0 | 0 | 1 | 1 |
Valuation
- –
- –
- –
- -18.0×
- 1.7×
- –
- –
- -33.4%
- -42.5%
- –
Profitability
- 53.2%
- -51.2%
- -72.9%
- –
- -76.4%
- -59.3%
- –
- –
- –
- –
Growth
- −8.9%
- –
- –
- –
- +91.0%
Financial health
- –
- -2.13
- –
- -4.9×
- 1.28
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 2%of 952
Bottom 7%of 883
Bottom 7%of 870
Bottom 1%of 985
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
17No pass
Benjamin Graham
13No pass
Philip Fisher
34No pass
Peter Lynch
0No pass
Joel Greenblatt
0No pass
Charlie Munger
24No pass
Terry Smith
22No pass
Questions about Allergy Therapeutics
Is Allergy Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Allergy Therapeutics AI analysis
What does Allergy Therapeutics do?
Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders in Germany, Austria, United Kingdom, Netherlands, Switzerland, Italy, Spain, and internationally. It is in Drug Manufacturers - Specialty & Generic, based in Worthing, United Kingdom, with 584 employees.
Is Allergy Therapeutics stock halal?
No. Allergy Therapeutics does not pass our halal screen: its debt is 64% of its market value, at or above the 33% limit. How we check
How has Allergy Therapeutics stock done over the past year?
Down 81.8% over the past twelve months, to £0.01. It traded between £0.01 and £0.12 and is 87.7% below its high.
Who are Allergy Therapeutics's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Allergy Therapeutics's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.